Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors

Quick, Allison; Zvinovski, Filadelfiya; Hudson, Catherine; Hundley, Andrew F.; Evans, Clifford; Suresh, Anupama; Arthur, Elizabeth; Ramaswamy, Bhuvaneswari; Reinbolt, Raquel E.; Noonan, Anne M.; VanDeusen, Jeffrey; Wesolowski, Robert; Stover, Daniel G.; Williams, Nicole; Sardesai, Sagar; Smith, Karen L.; Faubion, Stephanie S.; Loprinzi, Charles L.; Lustberg, Maryam B.

doi:10.1007/s00520-019-05211-3

Cited by 30 publications

(65 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Demographics, clinical data, and inclusion/exclusion criteria were obtained for all participants and have been previously reported [25]. All women were contacted for twoyear follow-up either by phone or during a routine clinic visit to medical oncology or urogynecology.…”

Section: Methodsmentioning

confidence: 99%

“…Women with non-metastatic breast cancer with symptoms of GSM including dyspareunia and/or vaginal dryness were recruited for this study as previously reported [25]. Patients had completed surgery, chemotherapy, and/or radiation for their breast cancer.…”

Section: Sample and Eligibilitymentioning

confidence: 99%

“…Fractional CO 2 laser treatment has also been used in women with cancer, most commonly breast cancer. Data based on retrospective [21][22][23] and several small single-arm studies have shown improvement in vaginal symptoms and sexual function [24][25][26][27][28]. A major limitation of these studies has been a lack of long-term follow-up to evaluate persistence of benefit of this intervention.…”

Section: Introductionmentioning

confidence: 99%

“…We conducted a pilot study of fractional CO 2 laser treatment in breast cancer survivors with GSM and demonstrated feasibility based on 88% of those enrolled completing all treatments according to protocol without serious adverse events. In addition, the treatment appeared to reduce symptoms of GSM at the initial one-month follow-up [25]. This study protocol was amended to collect follow-up data at one and two years to augment the limited long-term data on this treatment.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Long-Term Follow-Up of Fractional CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors

Quick

Hundley

Evans

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

(1) Background: The objective of this study was to determine the long-term efficacy of fractional CO2 laser therapy in breast cancer survivors. (2) Methods: This was a single-arm study of breast cancer survivors. Participants received three treatments of fractional CO2 laser therapy and returned for a 4 week follow-up. Participants were contacted for follow-up at annual intervals. The Vaginal Assessment Scale (VAS), the Female Sexual Function Index (FSFI), the Female Sexual Distress Scare Revised (FSDS-R), the Urinary Distress Inventory (UDI), and adverse events were collected and reported for the two-year follow-up. The changes in scores were compared between the four-week and two-year and the one-year and two-year follow-ups using paired t-tests. (3) Results: In total, 67 BC survivors were enrolled, 59 completed treatments and the four week follow-up, 39 participated in the one-year follow-up, and 33 participated in the two-year follow-up. After initial improvement in the VAS from baseline to the four week follow-up, there was no statistically significant difference in the VAS score (mean Δ 0.23; 95% CI [−0.05, 0.51], p = 0.150) between the four week follow-up and the two-year follow-up. At the two-year follow-up, the FSFI and FSDS-R scores remained improved from baseline and there was no statistically significant change in the FSFI score (mean Δ −0.83; 95% CI [−3.07, 2.38] p = 0.794) or the FSDS-R score (mean Δ −2.85; 95% CI [−1.88, 7.59] p = 0.227) from the one to two-year follow-up. The UDI scores approached baseline at the two-year follow-up; however, the change between the one- and two-year follow-ups was not statistically significant (mean Δ 4.76; 95% CI [−1.89, 11.41], p = 0.15). (4) Conclusions: Breast cancer survivors treated with fractional CO2 laser therapy have sustained improvement in sexual function two years after treatment completion, suggesting potential long-term benefit.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Sample and Eligibilitymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Long-Term Follow-Up of Fractional CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors

Quick

Hundley

Evans

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thereafter, a maintenance laser session can be proposed after several months or even a year, if efficacy decreases over time. Few studies have investigated the efficacy of vaginal laser in women with a previous history of breast cancer; most of them were retrospective or prospective cohorts [17][18][19][20][21]. In addition, the majority of studies stopped after 12 weeks of follow-up, so little is known on long-term effects and efficacy duration.…”

Section: Introductionmentioning

confidence: 99%

Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up

Veron

Wehrer

Annerose-Zéphir

et al. 2021

Breast Cancer Res Treat

View full text Add to dashboard Cite

Safety and efficacy of non-ablative CO2 laser treatment of vulvo-vaginal atrophy in women with history of breast cancer

Lami,

Alvisi,

Baldassarre

et al. 2024

Arch Gynecol Obstet

View full text Add to dashboard Cite

Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors

Cited by 30 publications

References 41 publications

Long-Term Follow-Up of Fractional CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors

Long-Term Follow-Up of Fractional CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors

Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up

Safety and efficacy of non-ablative CO2 laser treatment of vulvo-vaginal atrophy in women with history of breast cancer

Contact Info

Product

Resources

About